leadf
logo-loader
viewCo-Diagnostics

Co-Diagnostics wins European CE marks for Logix Smart coronavirus, influenza A/B tests

The Logix Smart ABC test kit is capable of simultaneous detection of and differentiation between influenza A, influenza B and SARS-CoV-2, the virus that causes COVID-19

Person in mask holding coronavirus blood sample
The CE marks allow the export and sale of both tests as IVDs to begin immediately in Europe, as well as in other markets around the world that accept it

Co-Diagnostics Inc (NASDAQ:CODX) announced Tuesday that its Logix Smart ABC (Influenza A/B, SARS-CoV-2) test and its Logix Smart SARS-CoV-2 multi-gene test were both awarded CE marks from European regulators, which allows the products to be sold as in-vitro diagnostics.

The Logix Smart ABC test kit is capable of simultaneous detection of and differentiation between influenza A, influenza B and SARS-CoV-2, the virus that causes COVID-19. 

Due to the similarity in symptoms between the common cold, the flu and COVID-19, even vaccinated patients exhibiting any of these related symptoms will still require testing for differentiation, the company said. For that reason, Co-Diagnostics expects there to be a market for its ABC test even after a COVID-19 vaccine is widely available.

READ: Co-Diagnostics sees 3Q net income surge as revenue rises from COVID-19 test sales

By comparison, Co-Diagnostic’s SARS-CoV-2 multi-gene test uses two gene markers, RdRp and E-gene, to identify the presence of SARS-CoV-2. 

"Since announcing that we were the first American company to receive a CE marking for a COVID-19 diagnostic, Co-Diagnostics has continued to provide high-quality molecular diagnostic solutions for the coronavirus worldwide,” CEO Dwight Egan said in a statement. “We are pleased to now announce additional tools in the ongoing battle against the pandemic, especially for those regions where government or regulatory bodies recommend a multi-target coronavirus diagnostic, such as in India."

Both tests use the company's patented CoPrimer technology and are designed for use with saliva and other respiratory tract samples, such as nasal swabs or sputum. They are each available for purchase from the company's Utah-based certified facility.

"Our CoPrimer technology is ideally suited for multiplexed PCR tests, as it dramatically reduces the possibility of 'primer-dimers,' a common phenomenon in PCR reactions that leads to false-positive results, and allowing for assays with much higher specificity,” Egan said. “With up to 56 million flu cases in the US alone in the last flu season, and with symptoms that are often similar to those of COVID-19, we believe that the need for a high-quality diagnostic tool capable of accurately detecting and differentiating between flu A/B and COVID-19 while also delivering true-negative results will remain strong.”

The CE marks allow the export and sale of both tests as IVDs to begin immediately in Europe, as well as in other markets around the world that accept a CE mark as valid regulatory approval, following routine local product registration.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Co-Diagnostics

Price: 12.14 USD

NASDAQ:CODX
Market: NASDAQ
Market Cap: $343.19 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Co-Diagnostics named herein, including the promotion by the Company of Co-Diagnostics in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Co-Diagnostics to reach wider audience with FDA Emergency Use Authorization...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the molecular diagnostics company's Logix Smart coronavirus test has obtained Emergency Use Authorization from the FDA to be used to diagnose SARS-CoV-2. Egan says the authorization confirms the quality and performance of the...

on 04/07/2020

3 min read